{
    "2014-03-24": [
        "I now think MRK is just 1 year behind GILD in HCV. MRK started ph3 today that could lead to 1st approval late 2015. All oral probably.",
        "Erbitux revenues are shared in US by LLY, BMY, and exUS by MRK. halo Already with RHHBY, PFE, and BAX. Who's Left?",
        "MRK - Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 & MK-8742 at EASL Annual"
    ]
}